Source comparison
Melanotan-2 Contraindications: Condition Comparison
The following table contrasts absolute versus relative melanotan-2 contraindications, the receptor mechanism driving each risk, and the clinical reasoning behind exclusion from research protocols. Cardiovascular disease (hypertension, arrhythmia, CAD) Absolute
This comparison does not assign a generated winner or score.
- The following table contrasts absolute versus relative melanotan-2 contraindications, the receptor mechanism driving each risk, and the clinical reasoning behind exclusion from research protocols.
- Cardiovascular disease (hypertension, arrhythmia, CAD)
- Absolute
- MC4R activation increases sympathetic tone, vascular resistance, heart rate
- Acute BP elevation 15–30+ mmHg; arrhythmia precipitation in susceptible substrates
- Exclude all subjects with documented CV disease; require baseline ECG and BP screening
- Pregnancy / lactation
- MC4R disrupts placental perfusion; MT2 crosses placenta and secretes into breast milk
- Fetal growth restriction, neural tube defects, neonatal MC receptor disruption
- Zero tolerance. Exclude all pregnant/nursing subjects; verify contraception in female participants
- Melanoma history or dysplastic nevi
- MC1R drives melanocyte proliferation via cAMP-MITF pathway
- Accelerates melanoma growth in pre-malignant or malignant cells; documented rapid progression cases
- Dermatological screening required; exclude subjects with personal/family melanoma history or >5 atypical moles
- Uncontrolled diabetes (HbA1c >8%)
- Relative
- MC4R modulates insulin sensitivity and glucose homeostasis
- Risk of hypoglycemia or hyperglycemia during dose titration
- Exclude poorly controlled cases; monitor glucose in controlled diabetics
- Severe renal impairment (eGFR <30)
- Reduced peptide clearance prolongs half-life and increases systemic exposure
- Dose accumulation increases cardiovascular and metabolic adverse event risk
- Exclude dialysis-dependent subjects; consider dose reduction in moderate impairment
- Concurrent antihypertensive use
- Additive or antagonistic BP effects depending on drug class
- MT2 may negate ACE inhibitor efficacy or potentiate beta-blocker hypotension
- Monitor BP closely; consider protocol exclusion if BP poorly controlled despite medication